Treatment-Resistant Depression | Ketamine/ Esketamine Program | Centerstone
cstnprapp14.centerstone.lan
Home / Depression / Ketamine/Esketamine Program for Treatment-Resistant Depression

Ketamine/Esketamine Program for Treatment-Resistant Depression

Centerstone has begun a new therapy program for individuals seeking treatment for severe depression at our Florida location.

About the Program

We are now certified to offer Spravato, a nasal spray that contains the FDA-approved medication Esketamine, and ketamine infusion therapy for people who have been treated for depression with no improvement in symptoms.

Both Spravato and ketamine infusion therapy are administered under the supervision of a medical professional, and patients are required to complete a comprehensive screening with a Centerstone physician prior to receiving treatment. Ketamine infusion therapy lasts approximately four hours for each dosage; Esketamine treatment takes approximately two hours.

Screenings and treatments are scheduled at our Bradenton, Fla., locations.

Patient Support

The Johnson & Johnson Patient Assistance Foundation Inc. (JJPAF) is an independent, nonprofit organization committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. For more information, visit jjpaf.org.

Once Spravato has been prescribed, Janssen CarePath can help you find the resources you may need to help get started on the medication and stay on track. For more information, visit janssencarepath.com.

Frequently Asked Questions

What are Ketamine and Esketamine?

  • Ketamine is a medication traditionally used for anesthesia during surgery that was approved for use in the United States in 1970. While it does have a history as a drug of abuse, it is a safe and valuable medication when properly administered by a trained medical professional.
  • Esketamine was introduced as an anesthetic in Germany in 1997 and was then marketed in other countries. It is part of ketamine but differs slightly on a molecular level.

How long have they been used to treat depression?

  • For the past decade or so, researchers began studying the use of ketamine as an application for Treatment-Resistant Depression (TRD). Studies indicated that ketamine was highly successful at reducing symptoms of depression; some indicated relief of symptoms in about 80% of people prescribed. Despite their molecular differences, ketamine and Esketamine act essentially the same in their uses and effectiveness for treating TRD. Esketamine was approved by the U.S. Food and Drug Administration (FDA) in March 2019 under the drug name SpravatoTM.

When should Esketamine be considered for use?

  • Esketamine is approved to treat Treatment-Resistant Depression, which is diagnosed in patients who have suffered at least one major depressive episode and have experienced at least two failed drug therapies.

How is Esketamine used in treatment?

  • Spravato (Esketamine) is a fast-acting nasal spray approved for use in conjunction with an oral antidepressant in adults with Treatment-Resistant Depression.

How long does the treatment take?

  • For Esketamine administration, patients will need
    • 2 treatments per week for the first month (8 total)
    • 1 treatment per week for the second month (4 total)
    • 1 treatment every two weeks for the third month (2 total)
  • The initial visit will take about 2 hours; each subsequent appointment will take about 3 hours each.

Does insurance cover treatment costs?

  • Your insurance provider may cover Esketamine or Spravato. By enrolling in Janssen CarePath, you can receive guidance on submitting claims so that Spravato can be considered under your pharmacy benefits.

Do I need a referral before seeking treatment?

  • If you think Esketamine may be a good fit for you, it is a good idea to talk with your health care provider, but a referral by a medical professional is not required.

When can I expect to see results?

  • Patients typically begin to feel the effects within a few hours of treatment to the day after treatment. If the treatment schedule is adhered to, most patients will continue to feel the effects for up to several months.

For More Information

To learn more about the Spravato nasal spray, including answers to frequently asked questions, go online to spravato.com.

In the News

To see a report from WFLA-TV about this program, click here.

Call Today

For more information about Spravato self-pay rates, ketamine infusion therapy and Centerstone’s depression care services or to make an appointment, call (941) 782-4610.

Interested in Ketamine/Esketamine Program for Treatment-Resistant Depression?

If you are in crisis, please call our crisis lines, call 911 or visit the nearest emergency room.

New Clients

If you’d like to make a new appointment to see one of our therapists, please give us a call.

Current Clients

If you would like to reschedule an existing appointment, you can reach the clinic directly.

Send a message

Messages sent through this form are monitored during regular business hours (Monday – Friday, 9 a.m. – 5 p.m. Central Time). Messages received outside of these hours will be responded to the next business day.


Related Posts

Centerstone Logo - 2020
Addiction

New Transitional Housing Initiative Launched

Over one year ago, in response to the opioid crisis, Centerstone opened its first Centerstone Recovery Center (CRC) in Lexington, Scott County, Indiana. The Scott County CRC is a 30-day inpatient addiction treatment program for women seeking recovery. Through this program, we’ve had the privilege of joining with over 300 women to change the course ...

Centerstone Logo - 2020
Indiana

Recovery and Resource Rally

Centerstone Indiana’s Child and Family Service team in Jennings County recently partnered with JC Cares to host a Recovery and Resource Rally in North Vernon. Twenty-five community partners shared information regarding their services with more than 125 local residents. JC Cares was formed by Darragh Wilson, Centerstone, Assistant Manager, Child and Family Team; Cheri Massey, Jennings County United Way director; ...

Centerstone Logo - 2020
Research Institute

Centerstone names Richard Shelton its Chief Science Officer, Jennifer Lockman its Chief Executive Officer of Research Institute

Centerstone recently announced that Richard C. Shelton, MD, has been named the chief science officer for the organization and Jennifer Lockman, PhD, will take over as chief executive officer for Centerstone’s Research Institute. Both positions are effective June 1. Dr. Shelton served as chief executive officer for the Research Institute for three years, during which ...

Florida

Roger Johnson Promoted to CAO for Centerstone Florida

Melissa Larkin-Skinner, Chief Executive Officer at Centerstone Florida, recently announced the promotion of Roger Johnson to Chief Administrative Officer. Johnson previously served as Senior Vice President of Medical Services and Managed Care. In his new role, Johnson will take on additional responsibilities for leading and promoting growth for Centerstone’s medical records and facilities. Since joining ...

Centerstone offering free telehealth sessions to military personnel, families in metro St. Louis, Southern Illinois

Centerstone, one of the nation’s leading behavioral health providers, is offering up to 12 free counseling sessions to military personnel and their families residing in the metro St. Louis area and all around Metro East Illinois and Southern Illinois. Available via telehealth (video or phone) by Centerstone’s Military Services division, these free counseling sessions are ...

Florida

Roger Johnson Named COO in Florida

Centerstone has announced the promotion of Roger Johnson to chief operating officer in Florida. Johnson previously served as regional chief administrative officer. In his new role, Johnson will oversee Centerstone’s operations in Florida, including medical, outpatient, and residential services. He will also oversee facilities management, help lead business development and marketing, and implement Centerstone’s strategies ...

Centerstone Logo - 2020

Centerstone awarded $2,000,000 grant for trauma-focused treatment in Southern Illinois

Centerstone Trauma Treatment and Training (CT3) program is now accepting clients. Centerstone was awarded a $2 million, five-year grant from the U.S. Department of Health and Human Services Substance Abuse and Mental Health Services Administration (SAMHSA) and Center for Mental Health Services to help clients who have experienced traumatic events in May. Centerstone used the ...

Centerstone Logo - 2020

Centerstone to use grant to connect clients to telehealth services

Centerstone will use a $9,978 grant to purchase tablets, iPhones, headsets, software and phone service for clients without internet access so they can use the organization’s expanded telehealth programs. Centerstone was awarded the $9,978.64 grant from The Arc of Illinois for time-limited projects to assist in filling gaps in services that people with intellectual and ...

Centerstone Logo - 2020

Mental health matters, now more than ever before

Mental Health Month has been observed in the United States every May since 1949. It’s a time for us, as a nation, to come together and fight the stigma associated with mental health conditions and those who have them or seek treatment for them. Mental Health Month serves as a reminder that mental illness is ...

Call Now